Protodioscin

**Cat. No.:** HY-N0799  
**CAS No.:** 55056-80-9  
**Molecular Formula:** C₅₁H₈₄O₂₂  
**Molecular Weight:** 1049.2  
**Target:** Others  
**Pathway:** Others  
**Storage:**  
- Powder  
  -20°C  3 years  
  4°C  2 years  
- In solvent  
  -80°C  6 months  
  -20°C  1 month

### Solvent & Solubility

In Vitro  
10 mM in H₂O

<table>
<thead>
<tr>
<th>Preparing Stock Solutions</th>
<th>Solvent Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td></td>
<td>0.9531 mL</td>
<td>4.7655 mL</td>
<td>9.5311 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td></td>
<td>0.1906 mL</td>
<td>0.9531 mL</td>
<td>1.9062 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td></td>
<td>0.0953 mL</td>
<td>0.4766 mL</td>
<td>0.9531 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

**Description**

Protodioscin, a major steroidal saponin in dioscoreae rhizome, has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.

**In Vivo**

Protodioscin (5 and 10 mg/kg) significantly improves glucose intolerance and reduced the levels of serum UA, BUN, Cr, TC and TG. Protodioscin significantly reduces renal concentrations of IL-1β, IL-6 and TNF-α by inhibiting the activation of nuclear factor-κB, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase and extracellular signal-regulated kinase¹. Protodioscin ameliorates the death rate, inhibits the increase in neurological deficit scores and infarct volume, and reduces the apoptotic nerve cells induced by MCAO in rats. Protodioscin attenuates the change of relevant apoptins, suppresses the release of pro-inflammatory cytokines in serum and reverses the protein expression of NF-κB (in nucleus and cytoplasm) and IκBα (in cytoplasm) induced by MCAO in rats². Protodioscin (0.5 mg/kg, i.p.) increases the coagulation time by appr 50 % as compared to that of high-fat diet control rats. Protodioscin possesses a promising effect in lowering the blood levels of both lipoproteins, especially LDL, thus resulting in a high ratio of HDL/LDL³.
After habituation for 7 days, the animals are randomly divided into either the control (n=10) or experimental (n=40) group. Mice in the control group receive drinking water and standard chow, while the experimental group receive 30% (w/v) fructose in drinking water and standard chow for 12 weeks. After 6 weeks, mice receiving high-dose fructose are divided into four subgroups: fructose group (treated with CMC-Na in a matched volume), allopurinol (Allo) group (administered 5 mg/kg allopurinol hydrochloride), protodioscin-5 (Pdio-5) group (administered 5 mg/kg protodioscin) and protodioscin-10 (Pdio-10) group (administered 10 mg/kg protodioscin). Dose of protodioscin is selected according to other reports and the clinical adult dose of DR. According to the pharmacopoeia of China, the dose of DR for human is 30 g/day. Equivalently, the calculated dose of DR based on respective body surface areas for rats is 2.6 g/kg/day. The average content of protodioscin in DR is 0.183%, and so the dose of protodioscin for rats is 4.76 mg/kg/day. Therefore, the 5 mg/kg/day is as low dose, and 10 mg/kg/day is as high dose in this study. All drugs are administered orally once daily between 9:00 and 11:00 a.m., continuously for 6 weeks.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA